Perlmutter Cancer Center at NYU Langone Health

@Perlmutter_CC

We combine visionary thinking and compassionate care with the science of treating cancer. An NCI-designated Comprehensive Cancer Center, part of @NYULangone

New York, NY nyulangone.org/locations/perl… Joined January 2022

475 Following 1.7K Followers 2.6K Posts

Latest posts 5

Perlmutter Cancer Center at NYU Langone Health @Perlmutter_CC Oct 30

What role might GLP-1 medications play in #CancerSurvivorship? Join @DrMelanieJay for an evidence-based discussion of emerging research on recurrence, treatment effects, cardiovascular health, and potential risks, including muscle loss & GI effects.

RSVP: bit.ly/4A7nus8

Perlmutter Cancer Center at NYU Langone Health @Perlmutter_CC Oct 27

Congratulations to Jessica Schulte, MD, PhD, who will be honored at @cbtf_org’s 2026 #DreamMakersGala tomorrow! 🎉

We’re proud to celebrate Dr. Schulte’s dedication to advancing neuro-oncology research & improving care for individuals affected by brain and spinal cord tumors.

Perlmutter Cancer Center at NYU Langone Health @Perlmutter_CC Oct 26

Wrapping up at #ESMO2026, PCC’s Salman Punekar, MD, (@salmanpuneka) and Manuel Hidalgo, MD, (@DrMHidalgo) present tarlatamab survival data in small cell lung cancer and findings on a novel KRAS G12D inhibitor for pancreatic cancer.

@myESMO @NYUGrossman

Perlmutter Cancer Center at NYU Langone Health @Perlmutter_CC Oct 24

Today at #ESMO2026, PCC’s Kristen Spencer, DO, (@kspencer725) presents research on novel targeted therapies for colorectal cancer, including KRAS G12D inhibitors and treatment approaches for MCC CRC.

@myESMO @nyugrossman

The image is a digital schedule for the ESMO 2026 conference on October 24 in Madrid, Spain. It is hosted by NYU Langone Health. Kristen Spencer, DO, will present a rapid oral session with two time slots. From 9:27–9:32 am, the topic is "1954RO – INCA3390, a TGFRxp2-PD-1 Bispecific Antibody, With Standard of Care (SOC) Anticancer Therapies for Microsatellite Stable Colorectal Cancer (MSS CRC)." From 3:17–3:22 pm, the topic is "790RO – Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor, in combination with cetuximab ± mTOJFOX6 in patients with KRASG12D-mutated colorectal cancer (CRC).

Perlmutter Cancer Center at NYU Langone Health @Perlmutter_CC Oct 23

We're proud to highlight the outstanding research being presented by @NYULangone experts at #ESMO2026 in Madrid, Spain.

Today Bhavana Pothuri, MD, (@BPothuri) discusses unmet needs after immunotherapy & evolving clinical practices for endometrial cancer. @myESMO @nyugrossman

Sure, here's an alternative text description:

"Presentation agenda for ESMO 2026 held on October 23, 2026, in Madrid, Spain. Hosted by NYU Langone Health. The schedule includes topics on cancer treatment and immunotherapy, with specific sessions on unmet needs, reviewing immunotherapy data, and mapping change from 10:43 a.m. to 7:45 p.m. Dr. Bhavana Pothuri is mentioned.